treatment of c57bl x dba/2 f ( hereafter called bd2f ) mice bearing ascitic mammary adenocarcinoma-755 ( adc-755 ) with [ 3h ] -5-fluoro-2'-deoxycytidine ( [ 3h ] fdcyd ) plus tetrahydrouridine ( h4urd ) resulted in antimetabolite pool sizes indicative of a tumor-selective , dual pathway metabolism of fdcyd via both cytidine deaminase and deoxycytidine kinase .
C0039677
tetrahydrouridine
C0010723
cytidine deaminase